Novo Nordisk’s $5.2 billion acquisition of Akero Therapeutics sits at the center of 2025’s hottest M&A space: MASH/metabolic disease. The deal, announced October 9, represents the largest of three major Fibroblast Growth Factor 21 (FGF21) analog acquisitions in five months. Across the broader landscape, 2025 pharma M&A activity reached approximately $70 billion in upfront consideration…
Eli Lilly acquires Verve Therapeutics in $1.3 billion deal, validating gene editing for heart disease
Eli Lilly and Co. has agreed to buy Verve Therapeutics Inc. for up to $1.3 billion, in a move that bolsters Lilly’s push into gene editing for cardiovascular conditions and signals renewed confidence in the sector. The all-cash tender offer values Verve at $10.50 per share upfront. That’s a 113% premium over the company’s 30-day…
The top 100 cell and gene therapy companies to watch in 2023
The cell and gene therapy sector is poised to deliver a wave of new therapies with the potential to cure rare and common diseases. As many as 13 new cell or gene therapies could be approved for use in the U.S., Europe, or both by the end of 2023. While manufacturing and regulatory challenges remain,…
50 leading cell and gene therapy companies
Cell and gene therapies promise to enable broad changes in the healthcare system over the next decade, prompting a growing number of cell and gene therapy companies to join the space. Consider that a cell therapy technique could eliminate the need for immunosuppressive drugs for some organ transplant patients. Cell and gene therapy companies also…